SCHEMBL742018

SCHEMBL742018

CCCC(=O)Nc1ccc(NC(=O)COc2ccc(Cl)cc2Cl)cc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.77
KMT2A Q03164 6/20 0.77
CYP1A2 P05177 1/20 0.69
CYP3A4 P08684 1/20 0.69
CYP2C19 P33261 1/20 0.69
NPSR1 Q6W5P4 1/20 0.69
L3MBTL1 Q9Y468 2/20 0.67
MAPT P10636 6/20 0.64
TSHR P16473 2/20 0.64
HSD17B10 Q99714 1/20 0.64
ACHE P22303 1/20 0.61
HPGD P15428 5/20 0.61
SMN1; SMN2 Q16637 4/20 0.61
MAPK1 P28482 4/20 0.61
LMNA P02545 3/20 0.61
POLB P06746 1/20 0.60
NPC1 O15118 1/20 0.58
TP53 P04637 1/20 0.58
PKM P14618 1/20 0.58
RAB9A P51151 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27374650 0.89 MEN1 (0.84) MEN1KMT2ACYP1A2CYP3A4CYP2C19
SCHEMBL10016463 0.87 MEN1 (1.00) MEN1KMT2ACYP1A2CYP3A4CYP2C19
SCHEMBL4297872 0.84 MEN1 (0.75) MEN1KMT2ACYP1A2CYP3A4CYP2C19
SCHEMBL4293548 0.83 MEN1 (0.74) MEN1KMT2ACYP1A2CYP3A4CYP2C19
SCHEMBL27374640 0.82 NPC1 (0.77) MEN1KMT2ACYP1A2CYP3A4CYP2C19
SCHEMBL5410284 0.82 MEN1 (0.72) MEN1KMT2ACYP1A2CYP3A4CYP2C19
SCHEMBL12218388 0.80 MAPT (0.72) MEN1KMT2ACYP1A2CYP3A4CYP2C19
SCHEMBL28051599 0.79 ACHE (0.80) MEN1KMT2ACYP1A2CYP3A4CYP2C19
SCHEMBL27492213 0.79 NPC1 (0.71) MEN1KMT2ACYP1A2CYP3A4CYP2C19
SCHEMBL4008116 0.79 MEN1 (0.64) MEN1KMT2ACYP1A2CYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3079680-A2 COMPOSITIONS AND METHODS FOR TREATING, PREVENTING AND DIAGNOSING CANCER AND OTHER PROLIFERATIVE DISORDERS Angiogenex, Inc. (US) 2016-10-19 EP disclosed
WO-2015089495-A2 COMPOSITIONS AND METHODS FOR TREATING, PREVENTING AND DIAGNOSING CANCER AND OTHER PROLIFERATIVE DISORDERS ANGIOGENEX, INC. (US) 2015-06-18 WO disclosed
US-8138356-B2 Chemical inhibitors of inhibitors of differentiation Angiogeney, Inc. (US) 2012-03-20 US disclosed
US-20090226422-A1 Chemical Inhibitors of Inhibitors of Differentiation ANGIOGENEX 2009-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090226422-A1 Chemical Inhibitors of Inhibitors of Differentiation BRAF, MAPK1, RAF1 MEN1 3968/4885KMT2A 3273/4885CYP1A2 3355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.